newsfilter
← Latest News
Earnings Call Transcripts·

Jefferies Global Healthcare Conference - BIOAGE LABS INC

  • Explicit Guidance:

    • IND Filing: On track to file an Investigational New Drug (IND) application for the APJ (Adiponectin Precursor Receptor agonist) program by the end of 2026.
    • Phase I Readout: Expected to release three-month Phase I safety and efficacy data (using the same dose as the DME trial) by the end of 2024.
    • QUEL-CV Trial Data: Anticipates data readout from the obesity/inflammation Phase II trial (testing 30mg, 60mg, and 90mg doses) by the end of 2024 to inform future dosing for peripheral indications.
    • New Indication Announcement: Plans to announce a new peripheral indication (distinct from cardiovascular) in 2026, to be selected based on QUEL-CV biomarker data.
    • Capitalization: Well-funded through current milestones with cash reserves of approximately $350 million, covering the NLRP3 pipeline, the new APJ program, and the unannounced peripheral indication.
  • Business-Segment Outlook:

    • NLRP3 (DME): Initiating Phase II trial (180 patients, US-based, 3-month duration) for Diabetic Macular Edema (DME) to evaluate 4-letter visual improvement (as monotherapy or combination with VEGF). Aims to capture the 30–40% of DME patients currently untreated due to injection aversion.
    • NLRP3 (Other Ophthalmology): Developing rationale for Geographic Atrophy (GA), Uveitis, and ME/MEZI; GA trials anticipated to be longer duration than DME.
    • NLRP3 (Obesity/Metabolic): Preclinical IND filing for APJ agonist to target obesity, leveraging a novel mechanism orthogonal to incretins to potentially preserve muscle mass or enhance weight loss in combination therapies.
    • Cardiovascular: Deprioritizing standalone cardiovascular outcome trials due to market dynamics (post-Zeus trial disappointment); will instead use the existing QUEL-CV trial data to support selection of a different peripheral indication with an approvable endpoint.
    • Pipeline Expansion: No specific financial guidance on revenues, but targets best-in-class status in oral NLRP3 inhibition (8% IL-1b inhibition in Phase I) and oral APJ agonist development.
  • Market and Competitive Outlook:

    • Ophthalmology Demand: Anticipates significant market expansion via oral therapy replacing/adjuncting intravitreal injections, addressing a "refractory" segment and the "untreated" 30–40% of DME patients.
    • Competitive Landscape (NLRP3): Acknowledges waning enthusiasm for NLRP3 following the Zeus trial but argues for the target's upstream benefits over single cytokine drugs (IL-1/IL-6) and the unique advantage of an oral formulation.
    • Competitive Landscape (Obesity): Highlights a "very open" market for novel mechanisms beyond incretins (GLP-1); no direct competitors identified for the specific oral APJ mechanism yet, though watching developments in amylin/magrolimab.
    • Structural Shift: Expectation that oral delivery will enable "watch and wait" strategies and potential dose sparing of injectables, expanding the total addressable market beyond current injection-only standards.
  • Macro / Industry Outlook:

    • Regulatory/Market Trends: Management notes that the industry is shifting toward "novel mechanisms" rather than established incretin pathways, creating a favorable environment for non-oral incretin alternatives.
    • Investor Sentiment: Recognizes skepticism surrounding NLRP3 due to high-cost cardiovascular trials but pivots the narrative toward high-value, oral-accessible indications (ophthalmology, metabolic) where efficacy endpoints are clearer and trials are shorter.
    • Inflammation Biology: Reinforces the structural necessity of upstream inhibition (NLRP3) for complex inflammatory diseases (DME, metabolic syndrome) where single-cytokine blockade is insufficient.
  • Strategic Initiatives:

    • APJ Program: Advancing a novel oral APJ agonist with zero structural similarity to the withdrawn Azelaprag to avoid prior liver toxicity issues; targeting muscle preservation and combination potential with incretins.
    • DME Pivot: Moving NLRP3 from cardiovascular to ophthalmology (DME first) to capitalize on oral administration advantages and faster clinical endpoints (3 months vs. multi-year CV outcomes).
    • Peripheral Indication Selection: Utilizing 2024 QUEL-CV data to select and launch a new peripheral indication in 2026, contingent on identifying the optimal dose (30mg vs. 60mg vs. 90mg) via biomarker induction.
    • Partnership Leverage: Maintains preclinical partnerships with Novartis and Lilly for target discovery; leveraging Lilly's prior obesity program experience as a proof-of-concept for combination strategies.
  • Risks and Headwinds to Outlook:

    • Cardiovascular Data: QUEL-CV trial data (to be read end of 2024) is critical for validating the mechanism in an obese/inflamed population; failure to demonstrate biomarker improvement could derail the peripheral indication strategy.
    • Efficacy Thresholds: In DME, a result below 3 letters of improvement may be insufficient to distinguish from placebo effects, though 3 letters is considered clinically meaningful for monotherapy.
    • Safety Concerns: Potential for off-target safety issues (e.g., infection risks with broad inflammation suppression) remains a monitorable risk, though Phase I data was described as "clean."
    • Clinical Failure: If the DME Phase II trial fails to meet power endpoints (4-letter improvement), the path to a pivotal Phase III trial is contingent on the data quality.
    • Market Acceptance: Risk of slow adoption if oral agents cannot demonstrate clear superiority or convenience over established injection regimens (VEGF/IL-6).
  • Management Tone on the Future:

    • Confidence Level: High confidence in the NLRP3 molecule's pharmacological profile (best-in-class brain/eye penetration, >90% target coverage) and the strategic pivot to ophthalmology.
    • Strategic Shift: Definitive move away from binary cardiovascular outcome trials to more agile, oral-first indications with faster decision nodes.
    • Optimism on Obesity: Expresses strong excitement about the "open" obesity mechanism space and the potential for the APJ program to become a best-in-class oral option, potentially in fixed-dose combination.
    • Capital Efficiency: Projects confidence in using current cash reserves ($350M) to fund the entire development plan without immediate dilution, citing the ability to "see through" to multiple data readouts.
  • Miscellaneous:

    • Molecule Differentiation: BG-102 (NLRP3) noted for best-in-class brain and eye penetration (0.7 Kpu/CSF ratio), potentially superior to competitors in accessing the blood-retina barrier.
    • Study Design: DME trial is independently powered for both monotherapy and combination with VEGF, with 90% power to detect a 4-letter improvement.
    • Future Combinations: The APJ agonist is specifically designed for potential combination with incretins (monotherapy or fixed-dose combo) to double weight loss and preserve muscle mass.
Company
BIOAGE LABS INC
Keywords
BIOAGE LABS INC